Jaguar Health

US: JAGX

$8.7m market cap

$1.43 last close

Jaguar Health is a pharmaceutical company marketing Mytesi (crofelemer) for diarrhea associated with HIV treatment. Additionally, the company is developing the drug for a range of other diarrhea indications and has developed a set of products using the drug for animal use.

Investment summary

We are initiating research on Jaguar Health, which is centered on the development and marketing of its drug crofelemer for diarrheal disorders. It is approved and marketed under the name Mytesi for non-infectious diarrhea in HIV patients receiving anti-retroviral therapy (ART) and drove almost all of the $4.4m in sales in 2018. The company hopes to expand to other indications, aims to initiate a pivotal study for targeted cancer therapy-related diarrhea (CTD) and plans to leverage results from an ongoing Phase II investigator-sponsored study. We initiate with a valuation of $86.5m or $4.14 per diluted share.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 4.4 (13.5) (15.0) (362.92) N/A N/A
2018A 4.4 (22.2) (24.9) (118.63) N/A N/A
2019E 7.0 (17.7) (29.8) (8.69) N/A N/A
2020E 9.7 (23.5) (26.6) (4.19) N/A N/A
Last updated on 16/09/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (US$m) 6.3
Forecast gearing ratio (%) 44
Price performance
%
1m
3m
12m
Actual 28.8 (76.9) (96.2)
Relative* 24.1 (77.8) (96.3)
52-week high/low US$117.6/US$1.1
*% relative to local index
Key management
Lisa Conte CEO & Founder